Comparison

Interferon-tau (IFN-tau), Ovine European Partner

Manufacturer GenScript
Category
Type Proteins
Specific against other
Format Sterile Filtered White lyophilized (freeze-dried) powder.
Amount 10ug
Item no. Z02790-10
Targets FAM20C, HLA-C, MAPT
eClass 6.1 34160400
eClass 9.0 42020190
Available
Specificity
Fully biologically active when compared to IFN-alpha. The specific activity determined by a viral resistance assay is no less than 1.0 x 107 IU/mg.
Description
IFN-tau is a new class of type I IFN that is secreted by the trophoblast and is the signal for maternal recognition of pregnancy in sheep. IFN- tau has potent immunosuppressive and antiviral activities similar to other type I IFN but is less cytotoxic than IFN-ª/ß. The current investigation concerns the effect of recombinant ovine IFN- tau (rOvIFN- tau) on the modulation of MHC class I and II expression on cloned mouse cerebrovascular endothelial (CVE) cells. IFN- tau induced tyrosine phosphorylation of Stat1 and upregulated the expression of MHC class I on CVE. One proposed action by which type I IFN reduce the relapse rate in MS is via interference with IFN-I³-induced MHC class II expression. IFN- tau was shown to downregulate IFN-I³-induced MHC class II expression on CVE and, hence, may be of potential therapeutic value in downregulating inflammation in the central nervous system (CNS). IFN- tau did not upregulate the expression of MHC class II on CVE. IFN- tau also inhibited the replication of Theiler's virus in CVE.
Endotoxin Level
Less than 0.2EU/ug of rOvIFN-tau as determined by LAL method.
Formulation
Lyophilized from a 0.2µ, m filtered concentrated, solution in PBS, pH 7.4.
M.W.
Approximately 19.9 kDa, a single non-glycosylated polypeptide chain containing 172 amino acids.
Product Line
Cytokine, Chemokines & Growth Factors
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °, C. Further dilutions should be made in appropriate buffered solutions.
Storage
This lyophilized preparation is stable at 2-8 C, but should be kept at -20 C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 C to -70 C. Avoid repeated freeze/thaw cycles.
Usage
This material is for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
Product Origin
USA

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10ug
Available: In stock
available

Delivery expected until 5/23/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close